Mushroom supplement may slow prostate cancer progression, City of Hope study finds

The Directors: NCORP PIs discuss workforce shortages, expanding workload, and crushing burden of regulatory oversight

Getting NCI clinical trials to the community has never been an easy task. Has it been getting simpler or more difficult in recent years?

May 29, 2026

Vol.52 No.21

By Paul Goldberg and Claire Marie Porter

In Brief

START Center for Cancer Research, Baptist Health South Florida expand patient access to early-phase clinical trials

Baptist Health South Florida and the START Center for Cancer Research, the largest global network of fully dedicated, early-phase oncology clinical trial sites, announced plans to form a strategic collaboration.

May 29, 2026

Vol.52 No.21

Clinical Roundup

Teclistamab extends OS, deepens remissions in landmark trial published in NEJM and presented at ASCO

Patients with relapsed multiple myeloma treated with the immunotherapy teclistamab (TECVALI) lived significantly longer and remained in remission far longer than those receiving standard therapies, according to results from a major international phase III clinical trial published in The New England Journal of Medicine and presented at the 2026 American Society of Clinical Oncology annual meeting.

May 29, 2026

Vol.52 No.21

Clinical Roundup

Adding a lower cutoff value for CA19-9 may identify additional high-risk cases of pancreatic cancer

A dual-threshold model for measuring the pancreatic tumor marker serum carbohydrate antigen 19-9 (CA19-9) identified patients with pancreatic cancer who had high-risk disease despite having low CA19-9 levels because of a genetic variation that impairs their ability to produce this biomarker.

May 29, 2026

Vol.52 No.21

Kennedy calls for a “moonshot” targeted on the role of the microbiome in cancer

Top HHS officials last week called for a “moonshot” focused on the role of the microbiome in cancer.

Imfinzi regimen reduced early disease recurrence in non-muscle-invasive bladder cancer, phase III trial POTOMAC shows

Exploratory analyses of the POTOMAC phase III trial showed adding one year of treatment with AstraZeneca’s Imfinzi (durvalumab) to BCG induction and maintenance therapy reduced the number of high-risk disease recurrences within the first year, with fewer BCG-unresponsive recurrences in patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer compared to BCG treatment alone.

May 22, 2026

Vol.52 No.20

Mushroom supplement may slow prostate cancer progression, City of Hope study finds

YOU MAY BE INTERESTED IN

The Directors: NCORP PIs discuss workforce shortages, expanding workload, and crushing burden of regulatory oversight

START Center for Cancer Research, Baptist Health South Florida expand patient access to early-phase clinical trials

Teclistamab extends OS, deepens remissions in landmark trial published in NEJM and presented at ASCO

Adding a lower cutoff value for CA19-9 may identify additional high-risk cases of pancreatic cancer

Kennedy calls for a “moonshot” targeted on the role of the microbiome in cancer

Imfinzi regimen reduced early disease recurrence in non-muscle-invasive bladder cancer, phase III trial POTOMAC shows

Renew today!

Subscriber content

Never miss an issue!

Login